Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Breast Cancer

Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer

Bone Marrow Transplantation volume 25, pages 1047–1052 (2000)Cite this article

Abstract

Doxorubicin plus paclitaxel has been shown to be an active regimen for metastatic breast cancer and is now frequently used as adjuvant therapy for high-risk primary breast cancer. Initial studies reported a higher than expected rate of cardiac toxicity with this regimen. We studied 105 patients with either high-risk primary breast cancer or metastatic breast cancer who were treated with doxorubicin (60 mg/m2) and 3-h infusions of paclitaxel (175 mg/m2) cycled every 3 weeks. Patients received three cycles of chemotherapy for high-risk primary or four cycles for metastatic disease. Patients then proceeded to high-dose chemotherapy (HDC) (STAMP I cyclophosphamide, cisplatin and carmustine) and peripheral blood progenitor cell transplantation (PBPCT). Patients underwent radionuclide multi-gated angiograms (MUGA) before and following induction chemotherapy and following HDC. During induction chemotherapy 40 (38%) of the patients had a reduction in left ventricular ejection fraction (LVEF). Fourteen had a decrease of 20% or greater and two were mildly symptomatic from CHF. There was additional reduction in the LVEF after HDC with a median value for LVEF of 59% (range, 20–78%). During HDC 10 patients developed clinical signs of congestive heart failure (CHF). Five patients responded to diuretic therapy and did not require any additional treatment. Four patients responded to vasodilation and/or digoxin with improvement in cardiac function. A clinically significant decrease in cardiac function was found in a small number of patients after induction chemotherapy and HDC with PBPCT. The majority of the patients tolerated this regimen without problems. Although there was a decline in LVEF as measured by radionuclide MUGA this did not prevent the majority of patients from proceeding with HDC. Bone Marrow Transplantation (2000) 25, 1047–1052.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Peters WP, Jones RB, Vredenburgh J et al. A large prospective, randomized trial of high-dose alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM) Proc Am Soc Clin Oncol 1996 15: 121 (Abstr. 149)

    Google Scholar 

  2. Buzdar AU, Holmes FA, Hortobagyi GN . Paclitaxel in the treatment of metastatic breast cancer: MD Anderson Cancer Center experience Semin Oncol 1995 22: 101–104

    CAS  PubMed  Google Scholar 

  3. Gianni L, Munzone E, Capra G et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines J Natl Cancer Inst 1995 87: 1169–1175

    Article  CAS  Google Scholar 

  4. Sledge GW, Robert N, Sparano JA et al. Paclitaxel (Taxol)/doxorubicin combination in advanced breast cancer: The Eastern Cooperative Oncology Group Experience Semin Oncol 1994 21: (Suppl.8) 15–18

    PubMed  Google Scholar 

  5. Amadori D, Frassineti GL, Zolli W et al. A phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer Semin Oncol 1996 23: 16–21

    CAS  PubMed  Google Scholar 

  6. Sledge GW . Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: The Eastern Cooperative Oncology Group experience Semin Oncol 1995 22: (Suppl.12) 123–125

    CAS  PubMed  Google Scholar 

  7. O'Shaughnessy JA, Fisherman JS, Cowan KH . Combination paclitaxel (Taxol) and doxorubicin therapy for metastaticbreast cancer Semin Oncol 1994 21: (Suppl.8) 19–23

    CAS  PubMed  Google Scholar 

  8. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumorefficacy and cardiac effects in a dose-finding and sequence-finding study J Clin Oncol 1995 13: 2688–2699

    Article  CAS  Google Scholar 

  9. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 1979 91: 707–710

    Article  Google Scholar 

  10. Shan K, Lincoff M, Young JB . Anthracycline-induced cardiotoxicity Ann Intern Med 1996 125: 47–58

    Article  CAS  Google Scholar 

  11. Hudis C, Riccio Lm Seidman A et al. Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel Cancer Invest 1998 16: 67–71

    Article  CAS  Google Scholar 

  12. Holmes FA, Valero V, Walters RS et al. The MD Anderson Cancer Center experience with taxol in metastatic breast cancer Monogr Natl Cancer Inst 1993 15: 161–169

    Google Scholar 

  13. Gianni L, Vigano L, Locatelli A et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer J Clin Oncol 1997 15: 1906–1915

    Article  CAS  Google Scholar 

  14. Goldberg MA, Antin JH, Guinan EC et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor Blood 1986 68: 1114–1118

    CAS  PubMed  Google Scholar 

  15. Steinerz LJ, Steinherz PG, Mangiacasale D et al. Cardiac changes with cyclophosphamide Med Pediatr Onco 1981 9: 417–422

    Article  Google Scholar 

  16. Kupari M, Volin L, Suokas A et al. Cardiac involvement in bone marrow transplant: electrocardiograpghic changes, arrhythmias, heart failure and autopsy findings Bone Marrow Transplant 1990 5: 91–98

    CAS  PubMed  Google Scholar 

  17. Peters WP, Stuart A, Klotman M et al. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study Cancer Chemother Pharmacol 1989 23: 377–383

    Article  CAS  Google Scholar 

  18. Ayash L, Wright JE, Tretyako O et al. Cyclophosphamide pharmocokinetics: correlation with cardiac toxicity and tumor response J Clin Oncol 1992 10: 995–1000

    Article  CAS  Google Scholar 

  19. Bearman SI, Petersen FB, Schor RA et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity Bone Marrow Transplant 1990 5: 173–177

    CAS  PubMed  Google Scholar 

  20. Hertenstein B, Stefanic M, Schmeiser T et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant J Clin Oncol 1994 12: 998–1004

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Center, Wayne State University School of Medicine, Detroit, Michigan, USA

    JL Klein, PMaroto Rey, RD Dansey, C Karanes, W Du, E Abella, L Cassells, C Hamm, WP Peters & RD Baynes

Authors
  1. JL Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. PMaroto Rey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. RD Dansey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Karanes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Abella
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Cassells
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Hamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. WP Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. RD Baynes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klein, J., Rey, P., Dansey, R. et al. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. Bone Marrow Transplant 25, 1047–1052 (2000). https://doi.org/10.1038/sj.bmt.1702394

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702394

Keywords

This article is cited by

Search

Advanced search

Quick links